Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating whether tenecteplase helps adults recover from an acute ischemic stroke when given more than 4.5 hours after the person was last seen well. This study focuses on people who had a stroke caused by a clot blocking a brain blood vessel and have imaging showing brain tissue that can still be saved. Participants are excluded if they are planned for a procedure to remove the clot. Participants are randomly placed into two groups. One group receives a single intravenous injection of tenecteplase, while the other group receives standard medical care. The trial compares these treatments to see if tenecteplase improves recovery when given later than the usual 4.5-hour window after stroke onset. Participants stay in the study for about three months, including roughly one week in the hospital. They undergo seven clinical visits or exams, with the last two likely done remotely from home. Doctors assess recovery using a scale that measures disability and dependence in daily life. They also monitor health and any side effects to compare outcomes between the two groups.
Actively Recruiting
Researchers are evaluating the real-world effectiveness and safety of Nebilet4 nebivolol in adults with hypertension across seven Asian countries. This multinational, multicenter, observational, and prospective study aims to assess blood pressure changes, treatment adherence, quality of life, prescription patterns, and cardiovascular outcomes over up to three years. The study also compares Nebilet4 used alone versus in combination therapy and investigates the relationship between home and office blood pressure measurements. Participants include about 5,000 adults newly diagnosed with or having uncontrolled hypertension who have recently started Nebilet4 or been on it no more than two weeks. Patients are followed regularly for 12, 24, and 36 months, with blood pressure measured at each visit and home readings encouraged. The study collects data on medication dosing and frequency, adherence, and cardiovascular risk factors, while monitoring major adverse cardiac events such as heart attack, stroke, and cardiovascular death. During the study, participants complete questionnaires to assess quality of life and medication adherence every few months. Data are recorded through an electronic system ensuring consistency across sites. Researchers evaluate changes in systolic and diastolic blood pressure and the proportion achieving target blood pressure goals. Safety and any adverse events are documented, with follow-up visits extending up to three years to provide insights into the long-term management of hypertension with Nebilet4.
Actively Recruiting
Researchers are comparing two medicines, tegoprazan and lansoprazole, to see which is better at healing bleeding peptic ulcers after 2 weeks of treatment in people in Indonesia. This study addresses a gap by directly comparing these two drugs, which work differently to reduce stomach acid, in a head-to-head trial. Peptic ulcer disease affects many people worldwide, and tegoprazan is a newer type of acid blocker that may work faster than traditional treatments like lansoprazole. Participants receive initial care including IV fluids, blood transfusions if needed, and high-dose acid-reducing medicine for the first 72 hours. Within 24 hours of hospital admission, they undergo a gastroscopy to examine the stomach and receive endoscopic hemostatic therapy if necessary. They are then randomly assigned to take either a 50 mg tegoprazan tablet plus a lansoprazole placebo, or a 30 mg lansoprazole capsule plus a tegoprazan placebo daily, 30 minutes before breakfast, for 14 days. If testing shows infection with H. pylori, participants receive additional antibiotic treatment. After 14 days, a second gastroscopy checks ulcer healing. During the study, participants are monitored daily for symptoms and rebleeding. They are reminded to take their medication and attend the follow-up gastroscopy, with contact made if needed. Researchers evaluate ulcer healing by comparing gastroscopy images taken before and after treatment. The main outcome measured is the mucosal healing rate on day 15 after starting treatment, with rebleeding rates also assessed within 14 days. The study lasts about 2 weeks of treatment plus follow-up evaluations.